However, the CheckMate-026 trial using nivolumab failed to show similar OS or progression-free survival (PFS) advantages [9], highlighting the limitations of PD-L1 as a standalone biomarker due to assay variability and tumor heterogeneity [6,10]. This evidence concerns the gene CD274 and neoplasm.